Weight-loss drugs to become cheaper? Dr Reddy’s generic entry may trigger price reset – Firstpost

India’s fast-growing anti-obesity drug market could also be headed for main pricing shake-up, with Dr Reddy’s Laboratories making ready to launch a generic model of semaglutide in March 2026 following patent expiry.

If executed aggressively on pricing, the transfer may materially decrease therapy prices in a section at the moment dominated by imported blockbuster manufacturers similar to Novo Nordisk’s Wegovy and Eli Lilly’s Mounjaro.

A blockbuster class in-built months

The previous yr has remodeled India’s metabolic remedy panorama.

Eli Lilly’s Mounjaro (tirzepatide), a twin GIP and GLP-1 receptor agonist, was launched in India on March 20, 2025, for weight problems, obese and Sort 2 diabetes. Positioned as a high-efficacy remedy, it rapidly gained traction amongst endocrinologists and weight problems specialists.

Inside months of launch, Mounjaro turned the highest-selling drug in India, clocking gross sales of over Rs 496 crore. Initially launched in vial format priced roughly between Rs 3,500 and Rs 4,375 relying on dosage, Lilly subsequently rolled out its KwikPen format to enhance comfort and drive accessibility.

Novo Nordisk entered the fray in June 2025 with Wegovy (semaglutide), intensifying competitors in what has develop into one of many fastest-growing remedy areas. Cipla, underneath a partnership with Eli Lilly, additionally launched its tirzepatide model Yurpeak, widening availability.

Excessive demand, restricted affordability

India has one of many largest populations globally dwelling with weight problems and Sort 2 diabetes. Urbanisation, sedentary life and dietary shifts have pushed metabolic issues to the forefront of public well being considerations.

Physicians report rising demand not simply from diabetics but additionally from youthful, city sufferers in search of structured medical weight administration. Nonetheless, excessive month-to-month remedy prices—working into a number of thousand rupees—have restricted penetration largely to metros and higher-income teams.

Insurance coverage protection for weight problems therapy stays patchy, and out-of-pocket spending dominates.

The generics inflection level

That’s the place Dr Reddy’s deliberate March 2026 entry turns into important.

Semaglutide, the lively ingredient in Wegovy, will divulge heart’s contents to generic competitors after patent expiry. Dr Reddy’s, with its sturdy observe document in advanced generics and injectables, is predicted to leverage home manufacturing scale and distribution power to compete aggressively.

“The presence of lower-cost semaglutide will certainly assist increasingly sufferers entry this drugs. At the moment, sufferers are attempting to make use of higher-cost variations with what I might name ‘Jugaad’ methods—micro-dosing the pen, taking lesser doses on a typical pen, or taking it much less steadily,” Dr. Subramanian Kannan, Director – Endocrinology and Diabetology at Narayana Well being Metropolis, Bengaluru, stated.

“The consequences of those sorts of practices are usually not recognized, and we hope that lower-cost semaglutide will assist extra sufferers be capable to take GLP-1s safely and profit from them,” he stated.

Traditionally, as soon as patents expire and Indian drugmakers enter a high-value section, competitors intensifies quickly. In a price-sensitive market like India, the arrival of a number of generics sometimes results in noticeable price rationalisation and wider affected person entry over time.

Ripple results on innovator manufacturers

Whereas generic semaglutide will instantly problem Wegovy, the pricing reset may have spillover results on tirzepatide as nicely.

Mounjaro at the moment enjoys sturdy model recall and scientific positioning owing to its dual-action mechanism.

Nonetheless, in a price-sensitive market, a considerably cheaper semaglutide various may affect prescribing selections, significantly if efficacy variations are perceived as marginal for sure affected person teams.